The Latest Breaking News from Amyris

After several big-name retailers failed to survive their Chapter 11 filings, one celebrity-backed brand may have hope.

In this crucial area of innovation, established companies and startups must work together to deliver the benefits that the science promises.

Upgrades

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

Clean health and beauty company Amyris (AMRS) is working with an immunotherapy company to accelerate the commercialization of a next-generation COVID-19 vaccine, which is expected to boost the company’s near-term prospects if approved. However, the stock has suffered a double-digit percentage price decline this year, closing the last session at…